Mawer Investment Management Ltd. Purchases 47,895 Shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY)

Mawer Investment Management Ltd. grew its position in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 7.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 683,733 shares of the medical instruments supplier’s stock after purchasing an additional 47,895 shares during the quarter. Mawer Investment Management Ltd. owned approximately 0.29% of DENTSPLY SIRONA worth $39,903,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of XRAY. Eos Focused Equity Management L.P. boosted its stake in DENTSPLY SIRONA by 177.6% during the second quarter. Eos Focused Equity Management L.P. now owns 57,857 shares of the medical instruments supplier’s stock worth $3,377,000 after acquiring an additional 37,012 shares in the last quarter. Achmea Investment Management B.V. bought a new position in DENTSPLY SIRONA during the second quarter worth $1,053,000. Altshuler Shaham Ltd boosted its stake in DENTSPLY SIRONA by 209.8% during the second quarter. Altshuler Shaham Ltd now owns 505 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 342 shares in the last quarter. Bbva USA Bancshares Inc. boosted its stake in DENTSPLY SIRONA by 19.6% during the second quarter. Bbva USA Bancshares Inc. now owns 9,354 shares of the medical instruments supplier’s stock worth $546,000 after acquiring an additional 1,532 shares in the last quarter. Finally, Hardman Johnston Global Advisors LLC bought a new position in DENTSPLY SIRONA during the second quarter worth $20,312,000. 94.13% of the stock is currently owned by institutional investors.

In other news, CEO Donald M. Jr. Casey bought 10,000 shares of the stock in a transaction dated Wednesday, May 29th. The stock was bought at an average price of $53.68 per share, for a total transaction of $536,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 105,631 shares in the company, valued at approximately $5,670,272.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Betsy D. Holden bought 2,720 shares of the stock in a transaction dated Thursday, June 6th. The stock was purchased at an average price of $55.31 per share, with a total value of $150,443.20. Following the acquisition, the director now owns 9,224 shares of the company’s stock, valued at $510,179.44. The disclosure for this purchase can be found here. Corporate insiders own 0.62% of the company’s stock.



XRAY traded down $0.78 during trading on Friday, hitting $52.17. 406,521 shares of the company’s stock were exchanged, compared to its average volume of 2,093,018. The company has a quick ratio of 1.39, a current ratio of 2.08 and a debt-to-equity ratio of 0.30. The business’s 50 day moving average is $54.92 and its two-hundred day moving average is $51.97. DENTSPLY SIRONA Inc has a fifty-two week low of $33.93 and a fifty-two week high of $59.40. The stock has a market cap of $11.91 billion, a P/E ratio of 25.96, a PEG ratio of 1.94 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, August 2nd. The medical instruments supplier reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.04 billion. DENTSPLY SIRONA had a net margin of 2.67% and a return on equity of 9.19%. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 earnings per share. On average, sell-side analysts forecast that DENTSPLY SIRONA Inc will post 2.39 earnings per share for the current year.

Several research firms have weighed in on XRAY. Wolfe Research began coverage on shares of DENTSPLY SIRONA in a report on Thursday, May 30th. They set a “peer perform” rating on the stock. BidaskClub upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Friday, August 16th. HC Wainwright restated a “neutral” rating and set a $57.00 price objective (up previously from $55.00) on shares of DENTSPLY SIRONA in a report on Tuesday, July 9th. ValuEngine downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Wellington Shields upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a report on Friday, August 2nd. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $54.57.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Read More: What are municipal bonds?

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.